Bexarotene Capsules — Class II drug recall D-1836-2019
Terminated recall by Upsher Smith Laboratories, Inc., reported 2019-08-28, distributed in KY, LA, NJ, OH. Failed Dissolution Specifications
| Recall number | D-1836-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Upsher Smith Laboratories, Inc., Maple Grove, MN, United States |
| Recall initiated | 2019-07-29 |
| Classified | 2019-08-19 |
| Reported by FDA | 2019-08-28 |
| Terminated | 2022-08-25 |
| Distributed | KY, LA, NJ, OH |
| Quantity | 166 bottles |
| Reason classes | specification failure |
| NDC | 00832-0285, 00832-0285-00 |
| Lot numbers | A2610 |
| Expiration dates | 2020-03 |
Product
Bexarotene Capsules, 75 mg, 100 capsules per bottle, Rx Only, Manufactured for: Upsher-Smith Laboratories, LLC, Maple Grove, MN 55369. NDC: 0832-0285-00
Reason for recall
Failed Dissolution Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1836-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.